Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
PrEPster joins call for PrEP for women

PrEPster today joined with other leading PrEP advocate organisations in calling for PrEP for women in the UK.

Published
21 August 2017
From
Prepster
Australia: PrEP listing decision deferred

An HIV prevention advocate has vowed to keep fighting for pre exposure prophylaxis to be PBS listed. The decision was deferred in order to seek further information regarding cost-effectiveness.

Published
21 August 2017
From
Australian Journal of Pharmacy
How PrEP changed Matt's life

The arrival of HIV/Aids in the 1980s had a devastating effect on gay communities around the world. Sexual intercourse was linked to the risk of contracting a deadly disease. We explore how pre-exposure prophylaxis (PrEP) has changed Matt's attitudes to sex.

Published
21 August 2017
From
BBC (video)
PrEP impact trial questions and answers

NHS England has announced the start of a pioneering implementation trial to provide HIV prevention drugs to people at high risk of HIV infection.

Published
21 August 2017
From
NHS England
Men on PrEP & HIV-positive men are getting hepatitis C during sex—here’s why

Hepatitis C is best known as an infection transmitted by blood, with most new cases of hepatitis C caused by sharing injection drug use equipment. But this dangerous infection, which … Read More →

Published
18 August 2017
From
BETA blog
How a Blue Pill Is Stopping the Spread of HIV

Gilead’s Truvada is preventing HIV, driving cases to 1980s low.

Published
18 August 2017
From
Bloomberg
PrEP use in US exceeds 100,000 in Gilead pharmacy survey

An estimated 120,000 people in the US have started Truvada for pre-exposure prophylaxis (PrEP) since 2012, according to the latest findings from a survey of

Published
14 August 2017
By
Liz Highleyman
Mylan launches 3 HIV generics in Canada

Mylan has launched three generics for treating HIV in Canada. Among the three launches is the company’s generic of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate, 200 mg/300 mg), as well as generics of Atripla (efavirenz, emtricitabine and tenofovir disoproxil fumarate, 600 mg/200 mg/300 mg) and Viread (tenofovir disoproxil, 300 mg).

Published
11 August 2017
From
Drug Store News
Can new 'Smart PrEP Pills' increase adherence for HIV-prevention medication among young people?

Researchers at Cook County Health and Hospitals System are currently recruiting participants in a study to see if, as expected, the smart PrEP pill makes it easier for young people to keep track of their PrEP dosage each day and in the process, significantly reduce their chances of getting HIV/AIDS.

Published
08 August 2017
From
Chicago Daily Herald
In first, healthcare provider to subsidize HIV medication

The decision by Meuhedet to subsidize a generic version of the drug Truvada is set to drive a dramatic drop in prices for HIV medication. Under the new policy, Meuhedet patients were expected to pay NIS 300-500 ($83-$138) for the medication instead of the current cost of some NIS 2,100 ($580).

Published
08 August 2017
From
The Times of Israel
← First12345...118Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.